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Human granulocytic anaplasmosis is a tickborne zoonosis caused by the bacterium 
Anaplasma phagocytophilum and first became a nationally notifiable human disease in 1999. In 
2008, the Connecticut Department of Public Health (CT DPH) added it to the list of reportable 
diseases for the state. In 2019, there was a three-fold increase in case counts compared to 
previous years. To understand trends in anaplasmosis and generate hypotheses regarding this 
increase, descriptive analyses were performed on confirmed cases reported to the CT DPH from 
2014 to 2019. Percentage of cases by gender, age, county, and month were calculated for each 
year, and chi-square analyses and two-sample t-tests were performed to discern statistically 
significant differences between cases in 2019 compared to cases from 2014 to 2018. Cases were 
mapped by zip code per year using ArcGIS Pro, and Anselin Moran’s I cluster analyses were 
performed. During 2014 to 2019, a total of 869 confirmed cases were reported to CT DPH; 315 
of those cases were reported in 2019. The majority of cases were male and aged 50-69 years. 
There was a statistically significant association between year and county of residence. While the 
county with the highest number of cases was Windham county in eastern Connecticut in 2014, 
by 2019, the majority of cases were in Litchfield and Fairfield counties in western Connecticut; 
case clusters were also detected in western Connecticut. This increase in cases may reflect a true 
increase in disease, increased laboratory testing and reporting, or a combination of these factors, 
particularly in western Connecticut. Future surveillance measures should aim to gather more 
comprehensive demographic information, reduce missing data, and collect clinical data in order 
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Background: 
Human granulocytic anaplasmosis—previously known as human granulocytic 
ehrlichiosis and renamed accordingly in 2001, following taxonomic modifications—is a 
tickborne zoonosis caused by the bacterium Anaplasma phagocytophilum.1,2,3 Signs and 
symptoms of anaplasmosis are nonspecific and may include fever, chills, headache, and 
malaise.4,5,6 Common laboratory findings associated with anaplasmosis include 
thrombocytopenia, leukopenia, or increased levels of liver enzymes, called hepatic 
transaminases.6  
While individuals diagnosed with anaplasmosis typically experience mild to moderate 
symptoms, severe illness may occur, particularly for those who delay treatment, possess 
underlying medical conditions, or who are older or immunosuppressed.7 The recommended 
treatment for all patients diagnosed with anaplasmosis is the antibiotic doxycycline; if treated 
appropriately, symptoms usually resolve within 48 hours, and the case-fatality rate for those who 
seek treatment is under one percent.2,4,7 
Humans can become infected with A. phagocytophilum via the bites of both nymphal and 
adult ticks; therefore, those individuals who live in or near tick habitats are most at risk for 
infection.8 In the United States, the primary vectors of anaplasmosis are the blacklegged tick, 
Ixodes scapularis, in the northeast and midwest, and the western blacklegged tick, Ixodes 
pacificus, in the west.8 Cases of anaplasmosis are most frequently reported in regions that 
coincide with the geographic range of the blacklegged tick, which is also the same vector that 
carries Borrelia burgdorferi and Babesia microti: the organisms responsible for Lyme disease 
and babesiosis.7 Consequently, co-infection may occur.7  
Anaplasmosis was designated as a nationally notifiable human disease in 1999.2 In 2008, 
the Centers for Disease Control and Prevention (CDC) established a new national notifiable case 
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definition for surveillance.9 According to this definition, a confirmed case is one that is 
laboratory confirmed and also meets clinical criteria, defined as presentation of fever in addition 
to at least one other specified symptom.9 Laboratory confirmation may involve any of the 
following: serological evidence of a four-fold change in IgG antibody to A. phagocytophilum 
antigens via indirect immunofluorescence assay (IFA); identification of DNA via polymerase 
chain reaction (PCR); discovery of the specified antigen during a biopsy or autopsy via 
immunohistochemical means; or isolation of the microorganism in cell culture.9  
In the state of Connecticut, where the blacklegged tick is endemic in all eight counties, 
the Connecticut Department of Public Health (CT DPH) has carried out surveillance for 
anaplasmosis since 1995.10,11 Past data have illustrated that most reported cases are adults, 
particularly those greater than 60 years of age.11 In 2008, the CT DPH added anaplasmosis to the 
list of reportable diseases for the state, after establishment of the surveillance case definition by 
CDC.12 During this time, anaplasmosis cases were reported by healthcare providers—via the 
Reportable Disease Confidential Case Report Form PD-23—and laboratories—via the 
Reportable Laboratory Findings Form OL-15C—to the CT DPH and subsequently entered into 
the Connecticut Electronic Disease Surveillance System (CTEDSS).13,14 Supplemental follow-up 
forms were also sent to ordering providers to obtain sufficient clinical information for case 
classification.  
In 2014, CT DPH changed its surveillance methods and case definition. Starting that 
year, healthcare providers were not required to report anaplasmosis, and laboratories were only 
required to report PCR positive cases; all other laboratory tests were no longer reportable.11 
Clinical follow-up, which involved the collection of clinical information by sending letters and 
supplemental follow-up forms to providers, was also discontinued that year; this decision was 
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made since response rates were low—with a small number of physicians mailing or faxing 
supplemental follow-up forms back—and disease incidence was steady. Despite this change, 
some physicians may still submit reports to CT DPH. Consequently, the current case definition 
utilized by the CT DPH differs from that of the national notifiable surveillance definition.11 
Since anaplasmosis first became a national reportable disease, the number of cases 
reported to the CDC has increased from 348 cases to 5,762 cases annually from 2000 to 2017, 
the majority of which have been reported amongst males and individuals over the age of 40 
during summer months.2 Recent studies have also reiterated a national increase of anaplasmosis 
from 2008 through 2012.4 In the northeast specifically, health departments in the states of Rhode 
Island and Massachusetts have reported an increase in anaplasmosis incidence in recent 
years.15,16 
In 2019, CT DPH observed a nearly three-fold increase in confirmed anaplasmosis cases 
compared to previous years. It is possible that this represents a true increase in incidence; 
alternatively, this observed increase could simply be attributed to an increase in laboratory 
testing and reporting or other underlying factors. This increase might also result from a 
combination of these possibilities.    
Therefore, the objective of this thesis is to perform a descriptive analysis of anaplasmosis 
surveillance data collected by the CT DPH from 2014 through 2019 in order to assess potential 
trends and to generate hypotheses regarding the reasoning behind this observed increase in cases. 
Subsequently, these analyses will inform recommendations for future surveillance of 






From 2008 to 2014, CT DPH defined cases according to the national notifiable case 
definition. As of 2014, a confirmed case is defined as one with A. phagocytophilum positive PCR 
test results. Given these specified changes in surveillance methods and the case definition, data 
examined for this study are limited to years 2014 through 2019, reflecting the period of time in 




Data collected by the CT DPH via the laboratory report form include demographic 
information—including age, gender, race, and ethnicity—in addition to geographic data, 
including street address, city, county, state, and zip code of patient residence. Temporal variables 
collected include symptom onset date, specimen collection date, laboratory report date, and the 
date that the case report is created in CTEDSS. An event date is calculated in CTEDSS based on 
availability of data in the following order: symptom onset data, specimen collection data, and 




PCR positive cases reported during 2014 through 2019 designated as residing within the 
state of Connecticut were included in the analysis. Cases with a complete absence of residential 
data or indicated as residing in states other than Connecticut were excluded from analysis. 
Although some physicians returned supplemental follow-up forms including symptom data, 
these represent less than 15% of cases, so clinical data was not included for analysis. Confirmed 
case counts reflected in this study may also vary slightly from those published by CT DPH in the 
past.  
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Analyses were performed to ascertain potential yearly trends by gender, age, and county. 
Case frequencies were calculated by gender, age, and county. Incidence rates (IRs) were 
calculated using population counts obtained from the 2010 United States Census.17 Race and 
ethnicity variables were excluded from analysis due to missing values for more than 70 percent 
of cases. Cases were classified by month as extracted from the event date variable, and case 
frequency was summarized by month for all six years collectively and also on a yearly basis. 
Chi-square analyses and two sample t-tests were conducted to determine statistical associations 
between demographic characteristic and case year as defined as the time period of 2014 through 
2018 versus 2019. Statistical significance was defined at the 0.05 level.  
Statistical analyses and calculations were performed and figures were produced using R 
3.5.3 and SAS 9.4 statistical software. 
 
GIS and Spatial Analysis 
 
The number of cases were aggregated by zip code. Geographic distribution of case 
numbers was plotted by zip code for all years using shapefiles obtained from Tiger/Line via the 
University of Connecticut’s Map and Geographic Information Center (UConn MAGIC).18 
Cluster analysis using Anselin Local Moran’s I, a measure of spatial autocorrelation, was also 
performed specifically on the collective distribution of 2014 through 2018 cases versus 2019 
cases to compare the presence of statistically significant case clusters during different time 
periods. Anselin Moran’s I cluster analysis determines if a specific feature location—in this case, 
zip code—neighbors features that reflect similar or different case counts and consequently 
indicates significance at the 0.05 level.19 If neighboring zip codes have similar values—whether 
those be high or low—they are classified as either high-high or low-low case clusters; if 
neighboring zip codes have very different values relative to one another, then they are defined as 
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outliers. Zip code features are otherwise indicated as not significant or as having an absence of 
data.  
The geographic distribution of cases was plotted and clusters analyses were performed 
using ArcGIS Pro 2.5. 
Results:  
 From 2014 to 2019, 869 confirmed cases of anaplasmosis were reported to the CT DPH. 
During 2014 to 2018, an average of 111 cases were reported per year. Specifically, in 2014, there 
were 127 cases (IR=3.6 per 100,000 persons), followed by 128 cases (IR =3.6) in 2015, 103 
cases (IR =2.9) in 2016, 88 cases (IR =2.5) in 2017, 108 cases (IR =3.0) in 2018, and 315 cases 
(IR =8.8) in 2019 (Table 1). While incidence rates remained relatively steady from 2014 to 2018, 
the incidence rate increased by nearly 200 percent from 2018 to 2019.   
 The mean age of cases for the entire sample was 60.0 years, with a standard deviation of 
17.3 years; this statistic was consistent within single years as well. Moreover, there was a wide 
range of ages represented; ages spanned from 4 years of age to 96 years of age. Among age 
categories across all years, the highest number of cases was aged 50-69 years—representing 
43.3% of the whole sample—followed by individuals 70 years and older, those aged 20-49 years, 
and lastly those individuals under the age of 20 (Table 2).  
Although the highest number of cases was observed among 50 to 69-year-olds, age-
specific incidence was highest among the oldest age group (Table 3). While the proportion of 
cases in each age group was fairly consistent from year to year, incidence rates across all groups 
increased substantially in 2019, corresponding with the overall increase in cases that year. 
Specifically, among individuals aged 70 or older, incidence jumped from 8.1 cases per 100,000 
persons annually in 2016, 2017, and 2018 to 29.4 cases per 100,000 persons in 2019.  
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 In regards to gender, case counts and incidence rates were consistently lower among 
females compared to males for all years of data (Table 2, Table 3). Approximately 60% of cases 
were male. While the ratio of male to female cases was mostly similar across all six years of 
data, there was an increase in incidence for both males and females in 2019, reflecting the total 
increase in case counts observed that year (Figure 1).   
 The majority of cases were reported during summer months (Table 5, Figure 2). From 
2014 to 2019, nearly 58% of all cases were reported in June and July; the next highest percentage 
of total cases across all years was reported in May (10.9%), followed by August (9.0%), then 
October (5.4%) and November (5.5%). With the exception of 2016, case counts peaked in June 
and July each year; in 2016, the highest number of cases occurred during the month of 
November (constituting 17.5% of cases that year), closely followed by June (15.5%) and October 
(13.6%) (Figure 3). In 2019, the most substantial increase in cases compared to previous years 
was observed in June and July. Specifically, in 2018, 31 and 17 cases were observed in June and 
July, compared to 102 and 120 cases in 2019. However, from year to year, the temporal 
distribution of cases as indicated by percentage of cases per month in a given year was relatively 
consistent, characterized by a large peak occurring at the summer months, accompanied by a 
smaller spike in cases around October and November (Figure 3).  
 Most notably, the spatial distribution of cases changed significantly during the observed 
six-year period (Figure 4). In 2014, a high number of cases as indicated by zip code occurred in 
northeastern Connecticut. As years progressed, the distribution of cases gradually shifted from 
northeastern Connecticut to western Connecticut. This change in spatial distribution is supported 
by the shift in case frequency distribution among county of residence from 2014 to 2019. From 
2014 to 2018, there was a higher proportion of cases with county of residence in Windham 
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county, the majority of which occurred in 2014, compared to 2019. Furthermore, when 
examining cases grouped from 2014-2018 versus 2019, chi-square analysis indicated a 
statistically significant association between county of residence and case year (p<0.001).  
In addition, Anselin Local Moran’s I cluster analyses detected statistically significant 
high-high case clusters specifically located in western Connecticut (Figure 5). From 2014 to 
2018 collectively, statistically significant high-high and low-low case clusters were detected; 
high-high case clusters were observed in western Connecticut. There were also several 
statistically significant outliers. In 2019, the western high-high case cluster expanded, and less 
low-low case clusters and outliers were detected. 
Discussion:  
This analysis examined demographic, temporal, and spatial trends in anaplasmosis cases 
from 2014 to 2019 as part of an effort to further understand the reasons behind the substantial 
increase in the number of reported cases in 2019 compared to those reported in previous years. 
While demographic and temporal trends were mostly conserved from year to year, there were 
notable differences in spatial distribution of cases by county and zip code of residence. 
The highest risk groups in this sample were males and older adults, particularly those 
more than 50 years of age; age-specific incidence was highest among those older than 70. These 
trends parallel those that have been reported in the literature by national agencies and state health 
departments.2,4,15,16,20 The higher incidence in males may be attributed to specific behaviors, such 
as propensity for outdoor work or a lower degree of engagement in tick protective measures; a 
study conducted in 2019 in Indiana noted gender differences in protective behaviors.21 
Furthermore, it is possible that the higher incidence observed in older age groups may reflect an 
association between disease severity and age; children may experience milder symptoms or none 
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at all, which may lead to underreporting of anaplasmosis in this age group, whereas more older 
adults might seek care for more severe symptoms.21 However, since our data lacked information 
regarding course of illness, it is difficult to make definitive conclusions regarding any 
associations involving disease severity. 
The seasonal distribution of cases illustrated in this analysis also mirrors what has been 
observed in previous studies and by other state health departments in the Northeastern United 
States.4,16,23,24 Most reported cases of anaplasmosis in this sample occurred during summer 
months, resembling the temporal distribution of other tick-borne diseases transmitted by the 
same vector, such as Lyme disease.24 The peak in cases observed during this time period not only 
corresponds with the increase in outdoor human activity that typically accompanies summer but 
also with the feeding stage of nymphal Ixodes scapularis. Given the smaller size and shorter 
feeding period—3 to 4 days—of the nymphal ticks, it is hypothesized that they may attach to 
humans undetected, facilitating disease transmission; thus, the nymphal stage is considered most 
“epidemiologically important”.24,25,26 Conversely, the smaller peak in cases around October 
coincides with the adult stage of the tick; adult ticks are larger and may be more noticeable and 
thus more prone to removal.8,25 Furthermore, in 2016, there was a high percentage of cases 
reported in the fall relative to the summer, a distribution which differed from previous years; this 
could possibly be attributed to a reporting delay, an increase in testing and reporting during that 
time, rising numbers in adult ticks, or changing distribution of tick reservoirs. However, it is 
unclear what is truly responsible for the change in temporal distribution observed that year. 
Numerous factors may be responsible for the substantial increase in cases observed in 
2019, particularly those associated with spatial distribution. Throughout the six-year study 
period, the geographic distribution of anaplasmosis as indicated by county and zip code changed 
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significantly. In 2014, most cases were concentrated in northeastern Connecticut, specifically in 
Windham county. In contrast, in 2019, the highest number of cases was found in two 
westernmost Connecticut counties: Litchfield and Fairfield. Anselin Moran’s I cluster analyses 
performed on the geographic distribution of cases for the five-year period of 2014 through 2018 
found statistically significant high-high case clusters in western Connecticut. In 2019, the 
western cluster further expanded. Together, these analyses indicate that zip codes in western 
Connecticut—even prior to 2019—have experienced a high number of cases relative to the rest 
of the state. These data therefore highlight the potential disproportionate burden of human 
granulocytic anaplasmosis experienced in western Connecticut and the possible importance of 
targeting those regions to reduce tick-borne disease. 
However, it is also possible that the perceived change in geographic distribution over 
time may simply be an artefact of case reporting. Providers in specific regions may have ordered 
more—or less—tests at certain points in time, which could account for fluctuations in case 
counts in eastern and western Connecticut from 2014 to 2019. In particular, an increase in 
laboratory testing could be responsible for the elevated number of cases from Litchfield and 
Fairfield counties in 2019; conversely, a decrease in testing could be responsible for the 
diminishing number of cases reported in eastern Connecticut. 
Certain underlying environmental factors could also be responsible for the shift in 
geographic distribution and the increase in the number of cases. Ixodes scapularis ticks prefer 
specific habitats, including deciduous forests and wooded vegetation, and animals such as the 
white-footed mouse serve as competent reservoirs for A. phagocytophilum.27,28 Changes in 
habitats which house ticks and their reservoirs, particularly those changes caused by human 
activity, may affect the suitability of these habitats for those species and prompt them to seek out 
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alternative refuge, which can impact the geographic distribution of disease. Forest fragmentation 
and destruction has further been linked to increased risk for tick-borne disease among humans.29 
It is also significant to note that parks, hiking trails, and other sources of recreational nature 
activities might be more common in certain regions of Connecticut, which could influence the 
probability that individuals venture into areas where they are likely to encounter ticks. 
These results may also reflect a true increase in cases. Studies have noted an increase in 
incidence over time.4,23 Furthermore, in recent years, health departments in states neighboring 
Connecticut have reported a similar upward trajectory in their number of reported cases. The 
Massachusetts Department of Public Health reported a 38 percent increase in confirmed and 
probable cases of anaplasmosis in 2017 compared to 2016; similarly, the Rhode Island 
Department of Health recognized a gradual increase in case frequency from 2013 to 2017.15,16 
The states of Vermont and Maine also noted an increase in anaplasmosis cases.30,31 The growth 
in cases over time may provide evidence for a general increase in anaplasmosis cases in the New 
England region. However, while it is possible that there has been a true increase in anaplasmosis, 
it is unlikely that this would account for the nearly three-fold increase in case counts in a single 
year; it is possible that this increase is partially supplemented by an increase in testing and 
reporting as well. 
Taking steps to understand the tick vector may help to interpret the trends in surveillance 
data. The Connecticut Agricultural Experiment Station (CAES) conducts passive surveillance by 
testing ticks submitted by Connecticut residents, health departments, and doctors’ offices for 
tick-borne pathogens, including A. phagocytophilum. From 2014 to 2018, the prevalence of 
Ixodes scapularis ticks infected with A. phagocytophilum increased, but there were no 
differences observed in spatial distribution of infected ticks.32 These conclusions may provide 
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evidence for a true increase in anaplasmosis, but they do not explain the spatial distribution 
illuminated in this analysis. However, a Massachusetts study found spatial associations with 
infected ticks; A. phagocytophilum-infected ticks were primarily located in eastern regions of the 
state.33 As the CAES commences active tick surveillance, it will be interesting to determine if 
these conclusions regarding spatial distribution of ticks in Connecticut change, and if the 
percentage of ticks infected with A. phagocytophilum coincides with the volume of human cases 
by geographic region.  
There were several limitations in this study. Firstly, there was a large amount of missing 
data on case reports, particularly in regards to race and ethnicity variables, which were excluded 
from analysis. Clinical data regarding symptom type and course of illness were available for a 
small subset of patients and were similarly excluded due to missing data. It is thus possible that 
there are underlying patterns or trends associated with characteristics that are missing from this 
data and therefore remain undetectable in this analysis. Furthermore, demographic and 
residential data were unknown for some cases; therefore, our conclusions may be susceptible to 
bias. In addition, since cases are reported via passive surveillance measures, the cases in this 
sample may not be representative of the entire population of cases, and case counts noted here 
may be lower than the true value.  
There were limitations associated with the spatial analyses conducted. Anselin Moran’s I 
analyses identify clusters based on values associated with neighboring features. Because the 
number of cases in each zip code in Connecticut was not known, many zip codes with known 
cases did not possess neighboring zip code features. Consequently, the lack of data could have 
impacted the accuracy of the provided results. Furthermore, since approximately 50 confirmed 
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cases were missing zip code data, it is possible that certain clusters or distributions remain 
undetected.  
The results of this analysis may present guidance for future surveillance. Completion of 
data collection may be essential in facilitating a complete understanding of the epidemiology of 
human granulocytic anaplasmosis in Connecticut and in formulating hypotheses for the 
substantial surge in cases observed in 2019. Furthermore, combining passive surveillance with 
active surveillance measures might be beneficial for case detection and fully characterizing the 
epidemiology of anaplasmosis.22 
These analyses, in conjunction with other studies, highlight the importance of pairing 
surveillance with GIS.34 Spatial analyses, paired with surveillance data, can play a critical role in 
identifying potential high-risk regions of disease. Future surveillance work in the context of 
anaplasmosis might benefit from investigating the landscape and environmental attributes in 
areas designated as having high-high case clusters, such as western Connecticut.34 
Epidemiologists have used remote sensing techniques to gain more information regarding vector 
habitats, including variables such as land use, land cover type, and temperature; furthermore, 
environmental data collected by organizations such as the United States Department of 
Agriculture (USDA) and the Connecticut Department of Energy and Environmental Protection 
(DEEP) may be useful for conducting additional environmental analyses. It might also be 
beneficial to examine how the geographic patterns of anaplasmosis in Connecticut compare to 
other diseases transmitted by the blacklegged tick.  
Certain methods could be implemented by CT DPH that would illuminate whether testing 
for anaplasmosis has changed over time in the state of Connecticut. Provider surveys could be 
distributed which ask providers to estimate how many tests they have ordered compared to 
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previous years and if their awareness of the disease has increased over time—factors which 
could influence fluctuations in case counts. Laboratory surveys could also be used to gauge if the 
number of test requests has increased. However, the receptiveness to a survey-based approach is 
questionable when response rates to clinical follow-up surveys were low. Nevertheless, similar 
surveys have previously been carried out in studies to gauge the extent of physician reporting for 
Lyme disease.36 
Clinical follow-up conducted by CT DPH will resume in 2020. From 2011 to 2014, the 
CT DPH noted that less than one third of follow-up forms were sent back by the ordering 
provider.11 As a result, certain measures could be implemented in an effort to educate and engage 
providers, encourage reporting compliance, and increase follow-up response rates. 
Communication outreach campaigns, which include newsletters, enhanced Web pages, digital 
media toolkits, and evaluation surveys have shown promising results for increasing reporting in 
the scope of disease surveillance, at least in the short-term.37 Employing such strategies could 
potentially be useful in the context of clinical follow-up. Furthermore, it is significant to note 
that collection of clinical data will be important in further characterizing the course of illness and 
understanding the epidemiology of cases reported to CT DPH; it could be possible that most 
reported cases are simply those that experience severe symptoms. 
Overall, it is likely that the upward trajectory in case frequency of anaplasmosis may be 
accounted for by some combination of a true increase in disease accompanied by changes in 
reporting behavior. However, it is difficult to draw definitive conclusions due to missing data 
and uncollected variables. Future surveillance measures should focus on collecting demographic 
and residential information, reducing missing data, gathering more clinical information, and 
ensuring compliance to future follow-up protocols such that more comprehensive analyses can 
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List of Tables:  
 
Table 1: Number of confirmed cases and incidence rates per 100,000 persons in Connecticut, 
2014-2019 
Year Cases (IR) 
2014 127 (3.6) 
2015 128 (3.6) 
2016 103 (2.9) 
2017 88 (2.5) 
2018 108 (3.0) 
































Table 2: Description of the sample, Connecticut, 2014-2019 













Gender        
   Male 522 (60.1) 79 (62.2) 76 (59.4) 61 (59.2) 47 (53.4) 71 (65.7) 188 (59.7) 
   Female 336 (38.7) 46 (36.2) 50 (39.1) 39 (37.9) 37 (42.0) 37 (34.3) 127 (40.3) 
   Unknown 11 (1.3) 2 (1.6) 2 (1.6) 3 (2.9) 4 (4.5) 0 (0.0) 0 (0.0) 
Age category        
     Under 20 24 (2.8) 6 (4.7) 4 (3.1) 3 (2.9)  2 (2.3) 2 (1.9) 7 (2.22) 
     20-49 185 (21.3) 26 (20.5) 29 (22.7)  19 (18.4) 19 (21.6)  26 (14.1) 66 (21.0) 
     50-69 376 (43.3) 53 (41.7) 53 (41.4) 51 (49.5) 32 (36.4) 51 (47.2) 136 (43.2) 
     70+ 267 (30.7) 37 (29.1) 38 (29.7)  29 (28.2)  29 (33.0) 29 (26.9) 105 (33.3) 
     Unknown 17 (2.0) 5 (3.9) 4 (3.1) 1 (1.0) 6 (6.8) 0 (0.0) 1 (0.3) 
County of residence        
    Fairfield 289 (33.2) 33 (26.0) 37 (28.9) 20 (19.4) 31 (35.2) 25 (23.1) 143 (45.4) 
    Hartford 36 (4.1) 5 (3.9) 2 (1.6) 6 (5.8) 8 (9.1) 10 (9.3) 5 (1.6) 
    Litchfield 180 (20.7) 12 (9.4) 10 (7.8) 15 (14.6) 15 (17.0) 28 (25.9) 100 (31.7) 
    Middlesex 2 (0.2) 0 (0.0) 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3) 
    New Haven 89 (10.2) 8 (6.3) 7 (5.5) 5 (4.9) 6 (6.8) 20 (18.5) 43 (13.7) 
    New London 67 (7.7) 15 (11.8) 16 (12.5) 14 (13.6) 4 (4.55) 10 (9.3) 8 (2.5) 
    Tolland 20 (2.3) 2 (1.6) 0 (0.0) 6 (5.8) 3 (3.4) 6 (5.6) 3 (1.0) 
    Windham 102 (11.7) 41 (32.3) 26 (20.3) 15 (14.6) 8 (9.1) 6 (5.6) 6 (1.9) 























Table 3: Incidence rates by characteristic per 100,000 persons, based on 2010 Census data, 
Connecticut, 2014-2019 













Gender        
   Male 522 (5.0) 79 (4.5) 76 (4.4) 61 (3.5) 47 (2.7) 71 (4.1) 188 (10.8) 
   Female 336 (3.05) 46 (2.5) 50 (2.7) 39 (2.1) 37 (2.0) 37 (2.0) 127 (6.9) 
Age category        
     Under 20 24 (0.4) 6 (0.7) 4 (0.4) 3 (0.3)  2 (0.2) 2 (0.2) 7 (0.8) 
     20-49 185 (2.2) 26 (1.8) 29 (2.0)  19 (1.3) 19 (1.3)  26 (1.8) 66 (4.6) 
     50-69 376 (7.1) 53 (6.0) 53 (6.0) 51 (5.8) 32 (2.65) 51 (5.8) 136 (15.5) 
     70+ 267 (12.5) 37 (10.4) 38 (10.6)  29 (8.1)  29 (8.1) 29 (8.1) 105 (29.4) 
County of residence        
    Fairfield 289 (5.3) 33 (3.6) 37 (4.0) 20 (2.2) 31 (3.4) 25 (2.7) 143 (15.6) 
    Hartford 36 (0.7) 5 (0.6) 2 (0.2) 6 (0.7) 8 (0.9) 10 (1.1) 5 (0.6) 
    Litchfield 180 (15.8) 12 (6.3) 10 (5.3) 15 (7.9) 15 (7.9) 28 (14.7) 100 (52.7) 
    Middlesex 2 (0.2) 0 (0.0) 1 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 
    New Haven 89 (1.7) 8 (0.9) 7 (0.8) 5 (0.6) 6 (0.7) 20 (2.3) 43 (5.0) 
    New London 67 (4.1) 15 (5.5) 16 (5.8) 14 (5.1) 4 (1.5) 10 (3.65) 8 (2.9) 
    Tolland 20 (2.2) 2 (1.3) 0 (0.0) 6 (3.9) 3 (2.0) 6 (3.9) 3 (2.0) 
    Windham 102 (14.4) 41 (34.6) 26 (22.0) 15 (12.7) 8 (6.8) 6 (5.1) 6 (5.1) 
















Table 4: Description of the sample: a comparison of data from 2014-2018 versus 2019 
  Year   
Characteristic 
2014-2018 
 (N* = 554) 
2019 
 (N = 315) p 
Age (years) 59.6 ± 17.3 60.6 ± 17.3 0.293 
Gender   0.597 
     Male 334 (61.5) 188 (59.7)  
     Female 209 (38.5) 127 (40.3)  
County of Residence   <0.001 
     Fairfield 146 (30.7) 143 (46.3)  
     Hartford 31 (6.5) 5 (1.6)  
     Litchfield 80 (16.8) 100 (32.4)  
     Middlesex 1 (0.2) 1 (0.3)  
     New Haven 46 (9.7) 43 (13.9)  
     New London 59 (12.4) 8 (2.6)  
     Tolland 17 (3.6) 3 (10.0)  
     Windham 96 (20.2) 6 (1.9)  


































January 4 (0.5) 2 (1.8) 0 (0.0) 0 (0.0)  2 (2.3) 0 (0.0) 0 (0.0) 
February 2 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.9) 0 (0.0) 
March 9 (1.0) 1 (0.8) 1 (0.8) 4 (3.9) 0 (0.0) 1 (0.9) 2 (0.6) 
April 38 (4.4) 2 (1.6) 5 (3.9)  5 (4.9)  1 (1.1) 14 (13.0) 11 (3.5) 
May 95 (10.9) 24 (18.9) 20 (15.6) 11 (10.7) 6 (6.8) 14 (13.0) 20 (6.3) 
June 259 (29.8) 48 (37.8) 34 (26.6) 16 (15.5) 28 (31.8) 31 (28.7) 102 (32.4) 
July 243 (28.0) 28 (22.0) 45 (35.2) 9 (8.7) 24 (27.3) 17 (15.7)  120 (38.1) 
August 78 (9.0) 10 (7.9) 9 (7.0) 10 (9.7) 9 (10.2) 15 (13.9) 25 (7.9) 
September 25 (2.9) 2 (1.6) 3 (2.3) 6 (5.8) 2 (2.3) 4 (3.7) 8 (2.5) 
October 47 (5.4) 3 (2.4) 8 (6.3) 14 (13.6) 8 (9.1) 6 (5.6) 8 (2.5) 
November 48 (5.5) 5 (3.9) 0 (0.0) 18 (17.5) 5 (5.7) 3 (2.8) 17 (5.4) 
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Figure 1: Incidence rate by characteristic and year, per 100,000 persons, of cases reported to CT 
DPH from 2014-2019. A. Incidence rate by gender. B. Incidence rate by age category. C. 
Incidence rate by county of residence. 
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Figure 3: A. Number of reported cases by month per year, Connecticut, 2014-2019.  B. 











Figure 4: Number of cases per year by zip code, Connecticut, 2014-2019. 
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